# Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

> **NCT01828476** · PHASE2 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 13 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** ABT-263
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT01828476
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2016-02
- **Final completion:** 2016-03-03
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The Investigator left the organization.
- **Last updated:** 2017-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01828476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01828476, "Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01828476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*